CSIMarket
 


Global Blood Therapeutics Inc.  (GBT)
Other Ticker:  
 
 

GBT's Income from Cont. Operations Growth by Quarter and Year

Global Blood Therapeutics's Income from Cont. Operations results by quarter and year




GBT Income from Cont. Operations (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - -87.58 -61.81 -95.98
III Quarter September - -70.99 -59.88 -64.55
II Quarter June -82.47 -69.59 -52.84 -57.32
I Quarter March -81.42 -74.93 -73.03 -48.92
FY   -163.89 -303.09 -247.56 -266.77



GBT Income from Cont. Operations second quarter 2022 Y/Y Growth Comment
Global Blood Therapeutics Inc. in the second quarter 2022 recorded loss from continued operations of $ -82.47 millions.

According to the results reported in the second quarter 2022, Global Blood Therapeutics Inc. achieved the best Income from Cont. Operations growth in Major Pharmaceutical Preparations industry. While Global Blood Therapeutics Inc.' s Income from Cont. Operations no change of % ranks overall at the positon no. in the second quarter 2022.




GBT Income from Cont. Operations ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Global Blood Therapeutics's second quarter 2022 Income from Cont. Operations $ -82.47 millions GBT's Income Statement
Global Blood Therapeutics's second quarter 2021 Income from Cont. Operations $ -69.59 millions Quarterly GBT's Income Statement
New: More GBT's historic Income from Cont. Operations Growth >>


GBT Income from Cont. Operations (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Income from Cont. Operations second quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Income from Cont. Operations second quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Income from Cont. Operations by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Global Blood Therapeutics's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


GBT's II. Quarter Q/Q Income from Cont. Operations Comment
Recent results of -82.47 millions by Global Blood Therapeutics Inc. appear even less good compare to the -81.42 millions loss from continued operations a quarter before.

Within Major Pharmaceutical Preparations industry Global Blood Therapeutics Inc. achieved highest sequential Income from Cont. Operations growth. While Global Blood Therapeutics's Income from Cont. Operations growth quarter on quarter, overall rank is .


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


GBT's II. Quarter Q/Q Income from Cont. Operations Comment
II. Quarter 2022 accomplishment of -82.47 millions by Global Blood Therapeutics Inc. appear even less good considering the -81.42 millions loss from continued operations a quarter before.

Within Major Pharmaceutical Preparations industry Global Blood Therapeutics Inc. achieved highest sequential Income from Cont. Operations growth. While Global Blood Therapeutics's Income from Cont. Operations growth quarter on quarter, overall rank is .


Global Blood Therapeutics's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Jun 30 2022)
12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
12 Months Ending
(Jun 30 2021)
Cumulative Income from Cont. Operations 12 Months Ending $ -322.46 $ -309.58 $ -303.09 $ -277.32 $ -266.21
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) - - - - -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # # # # #




Cumulative Income from Cont. Operations growth Comment
Global Blood Therapeutics Inc.' has realized cumulative trailing twelve months loss from continued operations of $ -322 millions in the Jun 30 2022 period.
The results are getting worse as the cumulative loss from continued operations is inflating from $ -309.58 millions in TTM ending quarter Mar 31 2022 and $ -249.457 millions for the twelve months ending in the quarter Jun 30 2021.

Global Blood Therapeutics Inc. achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Income from Cont. Operations growth Comment
Global Blood Therapeutics Inc.' has realized cumulative trailing twelve months loss from continued operations of $ -322 millions in the Jun 30 2022 period.
The business is worsening as the cumulative loss from continued operations is becoming larger from $ -309.58 millions for the period from Mar 31 2022 to Jun 30 2021 and $ -249.457 millions from the TTM period ending Jun 30 2021 Colin T. Miller wrote.

Global Blood Therapeutics Inc. achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Income from Cont. Operations Growth
Major Pharmaceutical Preparations Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
GBT's Income from Cont. Operations Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for GBT's Competitors
Income from Cont. Operations Growth for Global Blood Therapeutics's Suppliers
Income from Cont. Operations Growth for GBT's Customers

You may also want to know
GBT's Annual Growth Rates GBT's Profitability Ratios GBT's Asset Turnover Ratio GBT's Dividend Growth
GBT's Roe GBT's Valuation Ratios GBT's Financial Strength Ratios GBT's Dividend Payout Ratio
GBT's Roa GBT's Inventory Turnover Ratio GBT's Growth Rates GBT's Dividend Comparisons



Companies with similar Income from Cont. Operations no change for the quarter ending Jun 30 2022 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Jun 30 2022
Pacific Health Care Organization Inc 31.48%$ 31.478 millions
Globus Medical Inc 31.40%$ 31.400 millions
Integra Lifesciences Holdings Corp27.72%$ 27.718 millions
Teleflex Incorporated26.74%$ 26.743 millions
Medpace Holdings Inc 23.60%$ 23.604 millions
Charles River Laboratories International inc 23.07%$ 23.075 millions
Abbvie inc 20.68%$ 20.676 millions
Utah Medical Products Inc19.76%$ 19.761 millions
Zynex inc 19.16%$ 19.160 millions
Avantor Inc 18.76%$ 18.758 millions
Chemed Corporation17.58%$ 17.575 millions
Maravai Lifesciences Holdings Inc 16.66%$ 16.656 millions
Mettler toledo International Inc 14.78%$ 14.779 millions
Ensign Group Inc14.27%$ 14.274 millions
Stryker Corp10.81%$ 10.811 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com